{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:59:51Z","timestamp":1767135591283,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":78,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006663.pub3","type":"reference-entry","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T01:12:19Z","timestamp":1361581939000},"source":"Crossref","is-referenced-by-count":13,"title":["Enzyme replacement therapy for Anderson-Fabry disease"],"prefix":"10.1002","author":[{"given":"Regina P","family":"El Dib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory M","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD006663.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub3-BIB3|cit3","series-title":"American Thoracic Society International Conference; 2005","first-page":"[B65] [Poster:","article-title":"Improvement in cardiopulmonary exercise testing during enzyme replacement therapy in fabry disease [Abstract]","author":"Bierer","year":"2005"},{"key":"10.1002\/14651858.CD006663.pub3-BIB5|cit4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1023\/A:1010331404448","article-title":"International Fabry Disease Study Group. Enzyme therapy for Fabry disease [abstract]","volume":"24","author":"Desnick","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006663.pub3-BIB4|cit5","first-page":"98","article-title":"Fabry disease enzyme therapy: phase 3 and extension results [abstract]","volume":"24","author":"Desnick","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006663.pub3-BIB7|cit7","first-page":"158","article-title":"Severe glomerulosclerosis and proteinuria may influence response to therapy in fabry disease [abstract]","volume":"26 Suppl 2","author":"Lee","year":"2003","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub3-BIB8|cit8","first-page":"A22","article-title":"Aenzyme-supplementation therapy for Fabry disease: first possible treatment [abstract]","volume":"58","author":"Linthorst","year":"2001","journal-title":"The Netherlands Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD006663.pub3-BIB10|cit10","first-page":"174","article-title":"Fabrazyme clears globotriaosylceramide from the skin of fabry patients [abstract]","volume":"26 Suppl 2","author":"Thurberg","year":"2003","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"6","key":"10.1002\/14651858.CD006663.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006663.pub3-BIB12|cit12","first-page":"630","article-title":"Stabilization of renal function after enzyme replacement therapy in Fabry Disease [abstract]","volume":"18 Suppl 4","author":"Waldek","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"American Journal of Human Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006663.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"443","key":"10.1002\/14651858.CD006663.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1651-2227.2003.tb00217.x","article-title":"Hearing improvement in patients with Fabry disease treated with agalsidase alfa","volume":"92","author":"Hajioff","year":"2003","journal-title":"Acta Paediatrica"},{"key":"10.1002\/14651858.CD006663.pub3-BIB16|cit16","first-page":"S26","article-title":"Hearing loss in Fabry's disease: the effect of alpha-galactosidase A replacement therapy [abstract]","volume":"54 Suppl 7","author":"Hajioff","year":"2003","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1002\/14651858.CD006663.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"issue":"13","key":"10.1002\/14651858.CD006663.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.20550","article-title":"Enzyme replacement therapy and intraepidermal innervation density in Fabry disease","volume":"34","author":"Schiffmann","year":"2006","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1002\/14651858.CD006663.pub3-BIB22|cit22","first-page":"775","article-title":"Clinical effect of enzyme replacement in Fabry disease [abstract]","volume":"24","author":"Schiffmann","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"21","key":"10.1002\/14651858.CD006663.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006663.pub3-BIB24|cit24","doi-asserted-by":"crossref","unstructured":"Vedder AC Linthorst GE Houge G Groener JE Ormel EE Bouma BJ Online CONSORT checklist S1 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg' [online] PLoS One 2007 e598","DOI":"10.1371\/journal.pone.0000598"},{"key":"10.1002\/14651858.CD006663.pub3-BIB25|cit25","doi-asserted-by":"crossref","unstructured":"Vedder AC Linthorst GE Houge G Groener JE Ormel EE Bouma BJ Online supporting information to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg' [online] PLoS One 2007 e598","DOI":"10.1371\/journal.pone.0000598"},{"key":"10.1002\/14651858.CD006663.pub3-BIB26|cit26","doi-asserted-by":"crossref","unstructured":"Vedder AC Linthorst GE Houge G Groener JE Ormel EE Bouma BJ Online trial treatment protocol S1 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg' [online] PLoS One 2007 e598","DOI":"10.1371\/journal.pone.0000598"},{"key":"10.1002\/14651858.CD006663.pub3-BIB27|cit27","doi-asserted-by":"crossref","unstructured":"Vedder AC Linthorst GE Houge G Groener JE Ormel EE Bouma BJ Online trial treatment protocol S2 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg' [online] PLoS One 2007 e598","DOI":"10.1371\/journal.pone.0000598"},{"issue":"7","key":"10.1002\/14651858.CD006663.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD006663.pub3-BIB29|cit29","first-page":"62","article-title":"Enzyme replacement therapy in nine patients with Fabry disease","volume":"21 Suppl 11","author":"Alamartine","year":"2005","journal-title":"Medical Science"},{"key":"10.1002\/14651858.CD006663.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2005.04.009","article-title":"Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy","volume":"85","author":"Banikasemi","year":"2005","journal-title":"Molecular Genetics and Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD006663.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"European Journal of Clinical Investigation"},{"issue":"10","key":"10.1002\/14651858.CD006663.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD006663.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney international"},{"issue":"6","key":"10.1002\/14651858.CD006663.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1023\/B:BOLI.0000045841.27968.06","article-title":"Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy","volume":"27","author":"Cartwright","year":"2004","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study","volume":"28","author":"Eto","year":"2005","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006663.pub3-BIB37|cit37","first-page":"S227","article-title":"Safety and tolerability of agalsidase alfa in patients with Fabry disease formerly treated with agalsidase beta","volume":"34","author":"Fernhoff","year":"2011","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006663.pub3-BIB39|cit39","first-page":"116","article-title":"The clinical benefit of Fabrazyme treatment [abstract]","volume":"25 Suppl 1","author":"Guffon","year":"2002","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:BOLI.0000028726.11177.8b","article-title":"Clinical benefit in Fabry patients given enzyme replacement therapy - a case series","volume":"27","author":"Guffon","year":"2004","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"9","key":"10.1002\/14651858.CD006663.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2362.2006.01701.x","article-title":"Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey","volume":"36","author":"Hajioff","year":"2006","journal-title":"European Journal of Clinical Investigation"},{"issue":"7","key":"10.1002\/14651858.CD006663.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub3-BIB43|cit43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10545-006-0339-3","article-title":"Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease","volume":"29","author":"Jardim","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3B","key":"10.1002\/14651858.CD006663.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1590\/S0004-282X2006000500002","article-title":"White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up","volume":"64","author":"Jardim","year":"2006","journal-title":"Arquivos de Neuro-Psiquiatria"},{"key":"10.1002\/14651858.CD006663.pub3-BIB45|cit45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect os 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoshi","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub3-BIB46|cit46","first-page":"R5","article-title":"Influence of enzyme replacement therapy (ERT) on Anderson Fabry disease associated hypertrophic infiltrative cardiomyopathy (HIC)","volume":"161","author":"Kampmann","year":"2002","journal-title":"European Journal of Pediatrics"},{"key":"10.1002\/14651858.CD006663.pub3-BIB47|cit47","first-page":"166","article-title":"Safety of enzyme replacement therapy among 20 Japanese patients with classical type of Fabry disease [abstract]","volume":"28 Suppl 1","author":"Kobayashi","year":"2005","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1523-1755.2004.00883.x","article-title":"Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease","volume":"66","author":"Kosch","year":"2004","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub3-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006663.pub3-BIB50|cit50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfi221","article-title":"Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands","volume":"21","author":"Linthorst","year":"2006","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub3-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006663.pub3-BIB52|cit52","first-page":"163","article-title":"Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease","volume":"163","author":"Mills","year":"2004","journal-title":"European Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alfa in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatrica"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub3-BIB55|cit55","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD006663.pub3-BIB56|cit56","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1002\/14651858.CD006663.pub3-BIB58|cit58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clinical Genetics"},{"issue":"1-2","key":"10.1002\/14651858.CD006663.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cccn.2005.04.036","article-title":"Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments","volume":"360","author":"Utsumi","year":"2005","journal-title":"Clinica Chimica Acta"},{"issue":"11","key":"10.1002\/14651858.CD006663.pub3-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006663.pub3-BIB61|cit61","doi-asserted-by":"crossref","first-page":"S3-S47","DOI":"10.1016\/j.ymgme.2010.11.168","article-title":"Agalsidase alfa and agalsidase beta have similar effects on outcomes in Fabry disease - results from the Canadian Fabry disease initiative","volume":"102","author":"West","year":"2011","journal-title":"Molecular Genetics and Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD006663.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD006663.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006663.pub3-BIB65|cit65","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011) The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 20011"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","article-title":"Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?","volume":"96","author":"Hollak","year":"2009","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1002\/14651858.CD006663.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1740774508100984","article-title":"Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials","volume":"6","author":"Jones","year":"2009","journal-title":"Clinical trials"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD006663.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/0091270007305299","article-title":"Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents","volume":"47","author":"Ries","year":"2007","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub3-BIB70|cit70","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/heart.84.4.390","article-title":"A comparison of four quality of life instruments in cardiac patients: SF-36, QLI, QLMI, and SEIQoL","volume":"84","author":"Smith","year":"2000","journal-title":"Heart"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB71|cit71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"American Journal of Human Genetics"},{"key":"10.1002\/14651858.CD006663.pub3-BIB72|cit72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic Reviews in Health Care","author":"Sterne","year":"2001"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub3-BIB73|cit73","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0895-4356(99)00204-8","article-title":"Misleading funnel plot for detection of bias in meta-analysis","volume":"53","author":"Tang","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub3-BIB74|cit74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"Thornton","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genetics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub3-BIB76|cit76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Molecular Genetics and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub3-BIB77|cit77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub3-BIB78|cit78","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006663.pub2","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","author":"Dib","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006663.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T00:00:00Z","timestamp":1469404800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006663.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T07:29:08Z","timestamp":1714980548000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006663.pub3"}},"subtitle":[],"editor":[{"given":"Regina P","family":"El Dib","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":78,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006663.pub3","relation":{},"subject":[],"published":{"date-parts":[[2013,2,28]]}}}